The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-
controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy …

The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-
controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects …

The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol
Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled …

Abstract The Cholesterol Lowering Atherosclerosis Study (CLAS) is a prospective, placebo-
controlled, angiographic trial designed to test the hypothesis that aggressive lowering of …

A within-group risk factor analysis was conducted to predict angiographic change in the
Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of …

Background Progression of coronary artery disease is assumed to be a surrogate end point
for clinical coronary events. Because no single method or measure for a coronary …

Objective: To compare the effectiveness of the ternarydrug combination of colestipol, niacin,
and lovastatin with binary combinations of those drugs in treating patients with familial …

Colchicine, an antimitogenic agent, has shown promise in preventing restenosis after
coronary angioplasty in experimental animal models. A prospective trial was conducted …

Serum cholesterol-lowering ability and safety of colestipol hydrochloride were evaluated in a
randomized, placebo-controlled, multiclinic trial in 2278 hypercholesterolemic patients …

Objectives: The objective of this study was to determine whether colchicine 0.5 mg/day can
reduce the risk of cardiovascular events in patients with clinically stable coronary disease …